Cabaletta Bio(NASDAQ) CABA

Cabaletta Bio, Inc. makes therapies for people with autoimmune diseases. These treatments aim to fix the immune system with one dose. They focus on stopping harmful B cells.

The Pipeline and Platforms

• Resecabtagene Autoleucel: Lead therapy candidate designed to reset the immune system by depleting all B cells; currently in clinical trials for multiple conditions.
• CARTA Platform: Technology using engineered T cells, or Chimeric Antigen Receptor T cells for Autoimmunity, to potentially provide long-lasting responses for patients.
• CAAR T Platform: Specialized tool designed to target and remove specific harmful B cells while leaving healthy ones alone.
• DSG3-CAART: Clinical-stage treatment candidate for patients with mucosal pemphigus vulgaris, which is an autoimmune blistering skin disorder.

Building the Commercial Foundation

• Entered a worldwide license agreement with IASO in October 2022 to develop T cell products for autoimmune diseases.
• Partnered with Lonza and Cellares between 2024 and 2026 to expand cell processing and manufacturing capabilities.
• Raised $140.2 million in net proceeds through a public stock offering in May 2026 to fund clinical development.
• Agreed to use automated manufacturing technology through a clinical supply agreement with Cellares in January 2026.

Automation and Regulatory Assets

Cabaletta utilizes an automated manufacturing platform to produce therapies for thousands of patients with minimal capital investment. The company holds multiple FDA designations, including Fast Track and Orphan Drug status, for several of its leading clinical programs.

The Latest Financial Data

• Cash and cash equivalents totaled $225.1 million as of June 30, 2026.
• Net loss was $51.0 million for the three months ended June 30, 2026.
• Research and development expenses reached $44.4 million for the three-month period ended June 30, 2026.
• Accumulated deficit was $611.5 million as of June 30, 2026.

Bottom Line

Cabaletta has evolved from an early research firm into a late-stage clinical company with a focus on scalable manufacturing. Its strategy centers on developing one-time treatments to replace chronic therapy for autoimmune patients.